Executive Director, Investor Relations and Corporate Communications

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 13, 2026

Salary

$280K-$320K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$106,409 U.S. median for this role

Projected growth (BLS Employment Projections)

+7.7% - Faster than average

182% above the BLS role benchmark for finance aggregate.

Matched to SOC 13-2011 - Finance aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Finance From the posting source checked Jun 20, 2026

Seniority

Director Plus From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Public-company From the posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Executive Director, Investor Relations and Corporate Communications Bothell, Washington, United States Company Overview Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been submitted to the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-3050, an IND-cleared FAP-targeted radiotherapy; and IM-1617, an IND-cleared solid tumor ADC. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. Position Overview The Executive Director, Investor Relations will serve as the primary point of contact for the investment community and play a critical role in shaping Immunome's external communications strategy. Reporting to the Chief Financial Officer, this leader will be responsible for articulating the company's strategy, progress, and value proposition to investors, analysts, and other key financial stakeholders. The role requires deep understanding of the biotechnology sector and the ability to translate complex scientific and clinical information into clear, compelling narratives that enhance Immunome's visibility and credibility in the capital markets. Responsibilities Investor Relations - Execute the investor relations program in partnership with the CEO and CFO, ensuring clear, consistent, and disciplined communication with the capital markets. - Own day-to-day IR execution, including investor and analyst meeting coordination, targeting support, CRM management, feedback capture, and follow-up. - Draft all core IR

Read the full description at job-boards.greenhouse.io. FewerJobs shows a preview and links to the original posting.